Operating Lease, Right-of-Use Asset of Chemomab Therapeutics Ltd. from 01 Jan 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Chemomab Therapeutics Ltd. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 01 Jan 2019 to 30 Jun 2025.
  • Chemomab Therapeutics Ltd. Operating Lease, Right-of-Use Asset for the quarter ending 30 Jun 2025 was $0, a 100% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Chemomab Therapeutics Ltd. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $0 -$341,000 -100% 30 Jun 2025 6-K 14 Aug 2025 2025 Q2
Q4 2024 $289,000 -$103,000 -26% 31 Dec 2024 6-K 14 Aug 2025 2025 Q2
Q2 2024 $341,000 +$181,000 +113% 30 Jun 2024 6-K 21 Aug 2024 2024 Q2
Q4 2023 $392,000 +$165,000 +73% 31 Dec 2023 20-F 04 Apr 2025 2024 FY
Q2 2023 $160,000 -$135,000 -46% 30 Jun 2023 6-K 14 Aug 2023 2023 Q2
Q1 2023 $193,000 -$116,000 -38% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $227,000 -$118,000 -34% 31 Dec 2022 20-F 28 Mar 2024 2023 FY
Q3 2022 $261,000 -$98,000 -27% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $295,000 -$97,000 -25% 30 Jun 2022 10-Q 12 Aug 2022 2022 Q2
Q1 2022 $309,000 -$88,000 -22% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $345,000 -$83,000 -19% 31 Dec 2021 20-F 28 Mar 2024 2023 FY
Q3 2021 $359,000 +$125,000 +53% 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $392,000 +$117,000 +43% 30 Jun 2021 10-Q 13 Aug 2021 2021 Q2
Q1 2021 $397,000 +$58,000 +17% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $428,000 -$771,000 -64% 31 Dec 2020 10-K 30 Mar 2022 2021 FY
Q3 2020 $234,000 30 Sep 2020 10-Q 16 Nov 2020 2020 Q3
Q2 2020 $275,000 30 Jun 2020 10-Q 14 Aug 2020 2020 Q2
Q1 2020 $339,000 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $1,199,000 -$610,000 -34% 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q4 2018 $1,809,000 01 Jan 2019 10-K 17 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.